Source comparison
Melanotan-1 Dosage Protocol Guide: Comparison Table
Starting Dose 0.25mg 0.05mL (5 units) Tolerance assessment, first 5 days Minimal visible change; receptor priming phase 10–15% mild nausea, typically resolves within 48 hours Essential baseline. Skipping this phase increases side effect risk 3× Low Maintenance
This comparison does not assign a generated winner or score.
- Starting Dose
- 0.25mg
- 0.05mL (5 units)
- Tolerance assessment, first 5 days
- Minimal visible change; receptor priming phase
- 10–15% mild nausea, typically resolves within 48 hours
- Essential baseline. Skipping this phase increases side effect risk 3×
- Low Maintenance
- 0.5mg
- 0.1mL (10 units)
- Maintenance for fair-skinned subjects (Fitzpatrick I–II)
- Noticeable darkening by day 10–12 with UV co-exposure
- 5–10% transient nausea or facial flushing
- Minimum effective dose for most subjects; higher doses rarely needed
- Standard Maintenance
- 0.75mg
- 0.15mL (15 units)
- Maintenance for moderate skin types (Fitzpatrick III–IV)
- Visible pigmentation by day 7–10 with UV co-exposure
- 15–20% mild nausea; <5% spontaneous erections (males)
- Standard research dose; exceeding this provides diminishing returns
- Maximum Maintenance
- 1.0mg
- 0.2mL (20 units)
- Maximum dose; reserved for subjects unresponsive at 0.75mg
- Accelerated melanogenesis by day 5–7 with UV co-exposure
- 25–30% nausea; 10% spontaneous erections; 5–8% darkening of existing moles
- Ceiling dose. Further escalation increases off-target binding without additional benefit